Related Experiment Video
Updated: Sep 29, 2025
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
How satisfactory is on-demand icatibant from the patients' perspective in real life?
Insights
Patients with hereditary angioedema (HAE) report high satisfaction with icatibant treatment, finding it safe and effective for managing attacks. This real-world study supports encouraging icatibant availability for improved patient self-management.
Area of Science:
- Immunology and Allergy
- Pharmacology and Therapeutics
- Patient-Reported Outcomes
Background:
- Patient satisfaction is crucial for effective chronic disease management.
- Hereditary angioedema (HAE) is a chronic condition requiring effective treatment strategies.
- Icatibant is a treatment option for HAE attacks.
Purpose of the Study:
- To assess patient satisfaction with icatibant for hereditary angioedema (HAE) attacks.
- To evaluate the safety and effectiveness of icatibant in a real-world setting.
- To explore factors influencing patient satisfaction with icatibant treatment.
Main Methods:
- A questionnaire-based study involving 161 patients with HAE C1 esterase inhibitor (C1-INH) deficiency.
- Data collected included patient demographics, clinical features, attack frequency, and icatibant treatment details.
- Attack severity was assessed using a visual analog scale; patient satisfaction was self-reported.
Main Results:
- The majority of patients (91%) had HAE type I, experiencing a median of 2 attacks per month.
- Icatibant was self-administered by 91.3% of patients, with symptom resolution occurring approximately 1.7 hours post-administration.
- 77% of patients reported high satisfaction with icatibant; satisfaction correlated positively with attack severity, and no systemic reactions were observed.
Conclusions:
- Icatibant demonstrates safety and effectiveness in real-world HAE management.
- High patient satisfaction with icatibant suggests its value in improving quality of life.
- Encouraging icatibant availability empowers patients in managing their HAE attacks.
Abstract:
Background: Patients' satisfaction is important for the success of the management of chronic diseases. Objective: Our aim was to evaluate the satisfaction level of the patients with hereditary angioedema (HAE) for icatibant treatment. Methods: Patients with HAE C1 esterase inhibitor (C1-INH) were evaluated by using a questionnaire that included details of their icatibant-treated attacks. Patients' demographic and clinical features were collected from their medical records and personal attack diaries. The visual analog scale was used for determining the attack severity. Results: Of the total 161 patients with HAE C1-INH, 91% had HAE type I and were included in the study. Patients reported a median (interquartile range [IQR]) attacks of 2 (0.5-3) per month and 16 (4.5-36) attacks per year. The median (IQR) frequency of attacks treated with icatibant was 6 (0-20) per year. The mean ± standard deviation (SD) duration of treatment with icatibant was 3 ± 2.3 years. The self-administration rate was 91.3%. The mean ± SD time to administration and time to onset of symptom resolution were 1.6 ± 1.1 hours and 1.7 ± 1.3 hours, respectively. There was a correlation between the time to administration and time to onset of symptom resolution (r = 0.566; p < 0.0001). A total of 125 patients (77%) reported that they were very satisfied or satisfied with icatibant. No correlation was observed between the satisfaction level and the attack sites; however, the patients with more severe attacks were more satisfied with icatibant (p < 0.0001). A total of 52 patients reported 74 mild local reactions. Systemic reactions were not observed. Conclusion: The current real-life study showed that icatibant was safe and effective. Moreover, the patients' satisfaction level with icatibant was high. We believe that the availability of icatibant should be encouraged during HAE attacks because it enables patients to be more involved in their disease management.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Cardiac Catheterization IV: Nursing Management
01:29Venous Thrombosis III: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care
01:22Dose-Response Relationship: Potency and Efficacy